scholarly journals Development of an Fn14 agonistic antibody as an anti-tumor agent

mAbs ◽  
2011 ◽  
Vol 3 (4) ◽  
pp. 362-375 ◽  
Author(s):  
Jennifer S. Michaelson ◽  
Aldo Amatucci ◽  
Rebecca Kelly ◽  
Lihe Su ◽  
Ellen Garber ◽  
...  
Keyword(s):  
Agonistic Antibody ◽  
Tumor Agent

A Case of Malignant Lymphoma that Healed Completely after Oral Administrations of 4-Hydroxybenzaldehyde

2018 ◽  
Vol 1 (1) ◽  
pp. 01-02
Keyword(s):  
Cancer Patient ◽  
Malignant Lymphoma ◽  
Large Dose ◽  
Side Effect ◽  
Small Dose ◽  
Severe Hemorrhage ◽  
Tumor Agent

In 1969, Mutsuyuki Kochi [1, 2] developed 4-Hydroxybenzaldehyde for use as a novel anti-tumor agent without side effect and patent it. Accordingly, this medicine is capable of preventing carcinogenesis when used in sufficient quantity. To treat advanced cancers, an oncologist should start with giving the cancer patient a small dose of 4-Hydroxybenzaldehyde to avoid the possible severe hemorrhage of a tumor caused by excessive necrosis. Therefore, it has useful applications in treating lymphomas and leukemias. Consequently, those who have these diseases can receive a considerably large dose of the medicine.

scholarly journals Focused ultrasound in neuro-oncology: the role of the Focused Ultrasound Foundation in driving adoption and innovation

2021 ◽  
Author(s):  
Emily C. Whipple ◽  
Camille A. Favero ◽  
Neal F. Kassell
Keyword(s):  
Drug Delivery ◽  
Brain Tumors ◽  
Focused Ultrasound ◽  
Clinical Evidence ◽  
Neurological Injury ◽  
High Concentration ◽  
Potential Applications ◽  
Tumor Agent

Abstract Introduction Intra-arterial (lA) delivery of therapeutic agents across the blood-brain barrier (BBB) is an evolving strategy which enables the distribution of high concentration therapeutics through a targeted vascular territory, while potentially limiting systemic toxicity. Studies have demonstrated lA methods to be safe and efficacious for a variety of therapeutics. However, further characterization of the clinical efficacy of lA therapy for the treatment of brain tumors and refinement of its potential applications are necessary. Methods We have reviewed the preclinical and clinical evidence supporting superselective intraarterial cerebral infusion (SSJACI) with BBB disruption for the treatment of brain tumors. In addition, we review ongoing clinical trials expanding the applicability and investigating the efficacy of lA therapy for the treatment of brain tumors. Results Trends in recent studies have embraced the use of SSIACI and less neurotoxic chemotherapies. The majority of trials continue to use mannitol as the preferred method of hyperosmolar BBB disruption. Recent preclinical and preliminary human investigations into the lA delivery of Bevacizumab have demonstrated its safety and efficacy as an anti-tumor agent both alone and in combination with chemotherapy. Conclusion lA drug delivery may significantly affect the way treatment are delivered to patients with brain tumors, and in particular GBM. With refinement and standardization of the techniques of lA drug delivery, improved drug selection and formulations, and the development of methods to minimize treatment-related neurological injury, lA therapy may offer significant benefits for the treatment of brain tumors.

scholarly journals CD137 Signaling Is Critical in Fungal Clearance during Systemic Candida albicans Infection

2021 ◽  
Vol 7 (5) ◽  
pp. 382
Author(s):  
Vuvi G. Tran ◽  
Na N. Z. Nguyen ◽  
Byungsuk Kwon
Keyword(s):  
Candida Albicans ◽  
Defense Mechanisms ◽  
Tumor Necrosis ◽  
Fungal Infections ◽  
Fungal Growth ◽  
Wild Type ◽  
Agonistic Antibody ◽  
Innate Defense ◽  
Surface Receptor ◽  
Candida Albicans Infection

Invasive fungal infections by Candida albicans frequently cause mortality in immunocompromised patients. Neutrophils are particularly important for fungal clearance during systemic C. albican infection, yet little has been known regarding which surface receptor controls neutrophils’ antifungal activities. CD137, which is encoded by Tnfrsf9, belongs to the tumor necrosis receptor superfamily and has been shown to regulate neutrophils in Gram-positive bacterial infection. Here, we used genetic and immunological tools to probe the involvement of neutrophil CD137 signaling in innate defense mechanisms against systemic C. albicans infection. We first found that Tnfrsf9−/− mice were susceptible to C. albicans infection, whereas injection of anti-CD137 agonistic antibody protected the host from infection, suggesting that CD137 signaling is indispensable for innate immunity against C. albicans infection. Priming of isolated neutrophils with anti-CD137 antibody promoted their phagocytic and fungicidal activities through phospholipase C. In addition, injection of anti-CD137 antibody significantly augmented restriction of fungal growth in Tnfrsf9−/− mice that received wild-type (WT) neutrophils. In conclusion, our results demonstrate that CD137 signaling contributes to defense mechanisms against systemic C. albicans infection by promoting rapid fungal clearance.

Insights of Tris(2-pyridylmethyl)amine as anti-tumor agent for osteosarcoma: experimental and in silico studies

2021 ◽  
Vol 1228 ◽  
pp. 129773
Author(s):  
Marcos V. Palmeira-Mello ◽  
Juliana Lima Souza ◽  
Anthuan Ferino Pérez ◽  
Amanda dos Santos Cavalcanti ◽  
Suzana Assad Kahn ◽  
...  
Keyword(s):  
In Silico ◽  
In Silico Studies ◽  
Tumor Agent

Engineered NIR light-responsive bacteria as anti-tumor agent for targeted and precise cancer therapy

2021 ◽  
pp. 130842
Author(s):  
Huizhuo Pan ◽  
Lianyue Li ◽  
Gaoju Pang ◽  
Chunli Han ◽  
Baona Liu ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Nir Light ◽  
Tumor Agent

An agonistic antibody to EphA2 exhibits anti-tumor effect to human melanoma

2016 ◽  
Vol 84 (1) ◽  
pp. e85
Author(s):  
Atsushi Sakamoto ◽  
Kazunori Kato ◽  
Taro Kojima ◽  
Ritsuko Harigai ◽  
Toshio Hasegawa ◽  
...  
Keyword(s):  
Human Melanoma ◽  
Agonistic Antibody

Copper(II)-Girard's T complex as a promising anti-tumor agent

2010 ◽  
pp. n/a-n/a
Author(s):  
A. M. A. El-Sokkary ◽  
M. M. El-Naggar ◽  
A. F. Abdel-Aziz ◽  
M. M. Mostafa
Keyword(s):  
T Complex ◽  
Tumor Agent

The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo

2010 ◽  
Vol 22 (11) ◽  
pp. 2887-2893 ◽  
Author(s):  
A. Strube ◽  
M. I. Suominen ◽  
J. P. Rissanen ◽  
D. Mumberg ◽  
U. Klar ◽  
...  
Keyword(s):  
Tumor Agent

scholarly journals Trimebutine Promotes Glioma Cell Apoptosis as a Potential Anti-tumor Agent

2018 ◽  
Vol 9 ◽  
Author(s):  
Yi-pu Fan ◽  
Pei Liu ◽  
Wei-kang Xue ◽  
Wei-jiang Zhao ◽  
Hong-chao Pan
Keyword(s):  
Cell Apoptosis ◽  
Glioma Cell ◽  
Tumor Agent
Sign in / Sign up

Export Citation Format

Share Document